Efficacy of once-daily, high-dose, oral insulin immunotherapy in children genetically at risk for type 1 diabetes (POInT): a European, randomised, placebo-controlled, primary prevention trial

Journal:
The Lancet
Published:
Affiliations:
23
Authors:
129
Institutions Authors Share
Helmholtz Zentrum München - German Research Center for Environmental Health (HMGU), Germany
2.507576
0.12
German Center for Diabetes Research (DZD), Germany
2.462121
0.12
NIHR Oxford Biomedical Research Centre (OxBRC), United Kingdom (UK)
2.090909
0.10
Auf der Bult Centre for Children and Adolescents, Germany
2.045455
0.10
National Research Institute of Mother and Child (NRIMC), Poland
1.378788
0.07
TU Dresden, Germany
1.295455
0.06
Skåne University Hospital (SUS), Sweden
1.090909
0.05
Catholic University of Leuven (KU Leuven), Belgium
1.090909
0.05
University Hospitals Leuven (UZ Leuven), Belgium
1.045455
0.05
University Hospital Carl Gustav Carus Dresden, TU Dresden, Germany
1.045455
0.05
Ludwig Maximilians University of Munich (LMU), Germany
1.045455
0.05
Lund University (LU), Sweden
1.045455
0.05
TUM University Hospital Klinikum rechts der Isar (MRI), Germany
0.712121
0.03
University of Oxford, United Kingdom (UK)
0.545455
0.03
John Radcliffe Hospital, United Kingdom (UK)
0.545455
0.03
Medical University of Warsaw (MUW), Poland
0.378788
0.02
Dziecięcy Szpital Kliniczny, UCK WUM, Poland
0.378788
0.02
Paul Langerhans Institute Dresden (PLID), Germany
0.295455
0.01